CasNo.154229-18-2,Abiraterone acetate,17-(3-pyridyl)-5,16-androstadien-3beta-acetate(154229-18-2) Suppliers

1 Gram	Negotiable

Min.Order :1 Gram
Purity: 99% HPLC
Payment Terms : L/C|D/P|T/T

Keywords

Quick Details

Appearance:White or off-white solid
Application:Active Pharmaceutical Ingredient (API or Drug Substance) and products protected by valid patents in
PackAge:Fresco Bag / Polythene Bag
ProductionCapacity:100|Kilogram/Year
Storage:Store in tightly closed container in a cool and dark place. Or store solid and solutions at 4°C or -20°C for longer time storage.
Transportation:CIP/CPT/CIF/C&F Courier or by air

Superiority:

Recommendedintermediates,stockavailable,CAS32138-69-5,17-Iodoandrosta-5,16-dien-3beta-ol;98%HPLC;CAS154229-19-3,(3b)-17-(3-pyridinyl)-Androsta-5,16-di…

Details:

Recommended intermediates, stock available, CAS 32138-69-5, 17-Iodoandrosta-5,16-dien-3beta-ol; 98% HPLC; CAS 154229-19-3, (3b)-17-(3-pyridinyl)-Androsta-5,16-dien-3-ol; 99% HPLC; Our related patent application: 1.New process of Synthesis of Abiraterone acetate(CAS 154229-18-2), SIPO application No. 201210264405.7 2. Method of Purification of Abiraterone(CAS 154229-19-3), SIPO application No. 201210359996.6; Publication No.: CN102816201A. 3. An Improved Method of Synthesis of Abiraterone acetate(CAS 154229-18-2), SIPO application No. 201210356832.8 COA,NMR,HPLC: available by email ROS & MSDS: available with orders. Related information, From Wikipedia, the free encyclopedia Abiraterone is a drug used in castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) -- ie, prostate cancer not responding to androgen deprivation or treatment with antiandrogens. It is formulated as the prodrug abiraterone acetate and marketed under the trade name Zytiga.